The Lumanity team (then “BresMed”) supported the first successful HTA submissions to NICE in CAR T-cell therapy, and years on from the first approval, access to these innovative new therapies has expanded markedly. To help understand how countries currently evaluate established novel therapies, we have produced a whitepaper examining the primary factors that drive reimbursement decisions for CAR T-cell therapy across the US, UK and EU4 (France, Germany, Italy and Spain).

Fill out the form on the right to download the paper

Download the pdf

"*" indicates required fields

Sign me up to receive regular insights from Lumanity
This field is for validation purposes and should be left unchanged.